Developer docs
API playgroundTry for free, no card

Search company profiles

Astorg

Full company profile

uuid000058k

Namestring
Astorg
Legal namestring
ASTORG PARTNERS
Websiteurl
astorg.com
Company typeenum
Private
Founded yearint
1998
Descriptiontext

Astorg is a pan-European private equity firm founded in 1998 by Thierry Timsit and headquartered in Paris, France, with additional offices in London, Frankfurt, Milan, Luxembourg and New York. The firm operates through three wholly-owned regulated entities — Astorg Partners (AMF-regulated in France since 1998), Astorg Asset Management (CSSF-regulated in Luxembourg since 2015), and Astorg Advisory LLC (US sub-advisory) — and manages a fund family spanning eight generations of flagship buyout funds, a mid-cap vehicle, and continuation funds, reaching €24bn of assets under management with a 27% gross annualized return since inception across 27 years of investing.

Astorg's core products are its investment funds, which acquire majority stakes in global B2B companies: the Astorg VIII flagship buyout fund (€4.4bn, 2023 vintage) targets companies valued at €500m+; Astorg Mid-Cap (€1.3bn, 2022) targets €100-€400m companies; and continuation funds (Astorg Normec €1.4bn, Astorg IQ-EQ) provide liquidity and growth capital to existing portfolio companies. The firm invests across four verticals — healthcare, technology, business services, and technology-based industrials — with notable platforms including CordenPharma (pharmaceutical CDMO), IQ-EQ (investor services), Solina (food ingredients), Audiotonix (professional audio), Acturis (insurance SaaS), Fenergo (KYC/CLM), EcoVadis (sustainability ratings), Normec (TICC), and pending acquisitions of Thermo Fisher's microbiology business, Barkene, and Steliau/Acal BFI.

Astorg generates revenue primarily through recurring management fees on assets under management across its flagship, mid-cap and continuation fund vehicles, supplemented by performance-based carried interest participation in fund profits (supporting the reported 27% gross annualized return) and transaction-related fees on co-investments with limited partners. The firm serves institutional LPs (pension funds, insurance companies, asset managers, sovereign wealth funds, endowments and family offices) and operates an ancillary venture philanthropy arm, Astorg Philanthropy Investments, which deploys €30k-€300k cheques into health and accessibility-focused organizations under the King Baudouin Foundation. In April 2026, Astorg executed an 'internal LBO' granting new partners nearly 50% of firm equity while Thierry Timsit remained Executive Chairman, marking a generational ownership transition.

Short descriptiontext

Astorg is a pan-European private equity firm managing €24bn AUM across flagship, mid-cap and continuation buyout funds, investing in global B2B companies across healthcare, technology, business services and industrials. Founded in 1998 and headquartered in Paris, it serves institutional limited partners and has delivered a 27% gross annualized return since inception.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersParis, France
HQ citystring
Paris
HQ countrystring
France
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
private equity investing, buyout fund management, mid-market acquisitions, healthcare technology investing, business services investing
Industry2 codes
PRIMARYFSANALAI
Operator-Led / CEO-in-Residence ETA
Financial & Insurance/Private Equity & Venture Capital/Search Funds / Entrepreneurship Through Acquisition (ETA)
SECONDARYFSANALAH
Family Office–Backed ETA
Financial & Insurance/Private Equity & Venture Capital/Search Funds / Entrepreneurship Through Acquisition (ETA)
NAICS code1 code
  • Portfolio Management and Investment Advice52394
SIC code1 code
  • Investment Advice6282
Product category
Private Equity Fund Management
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1Management Fees
TypeSubscription Recurring
Description

Recurring fees charged on assets under management across flagship, mid-cap and continuation funds (e.g., Astorg VIII €4.4bn, Astorg VII €4.2bn, Astorg Mid-Cap €1.3bn, Astorg Normec Continuation Fund €1.4bn). Management fees fund the Astorg Philanthropy Investments arm.

astorg.com
2Carried Interest
TypeManaged Services
Description

Performance-based participation in fund profits, supporting the firm's reported 27% gross annualised return since 1998 across multiple fund vintages.

astorg.com
3Co-Investment Fees and Revenues
TypeTransaction Fee
Description

Meaningful co-investment opportunities offered to investor partners as an integral part of the value creation proposition; Astorg has invested over €19bn in businesses including co-invests.

astorg.com
4Alternative Investment Fund Management Fees
TypeSubscription Recurring
Description

Fees from managing FPCI/AIF funds subject to French law and Luxembourg-law AIFs via Astorg Asset Management (CSSF-regulated).

astorg.com
Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Pricing details2 tiers
1PRIIP Key Information Documents published for Astorg VII, Astorg MidCap and Astorg VIII
ModelOther
Notes

Specific fee structures contained within the KIDs; not summarised publicly on the website.

astorg.com
2Astorg Philanthropy Investments (API) cheque size range
ModelOther
Notes

Between €30k and €300k per organisation, structure can be grants, equity, debt, blended finance, fund investments.

astorg.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 3 records shown
1Astorg Mid-Cap
Description

Astorg's separately marketed mid-market fund family for investments valued between €100m and €400m; raised as a €1.3bn fund vehicle in 2022.

astorg.com
+2 more records
Core offering1 text field

Astorg is a private equity firm that raises and manages buyout fund vehicles — flagship (Astorg VIII €4.4bn), mid-cap (Astorg Mid-Cap €1.3bn), and continuation funds (Astorg Normec €1.4bn, Astorg IQ-EQ) — and deploys that capital to acquire majority equity stakes in global B2B companies valued between €100m (mid-cap) and €500m+ (flagship), headquartered in Europe or the US, across four sectors: healthcare, technology, business services, and technology-based industrials. The firm also operates Astorg Philanthropy Investments (API), a venture philanthropy arm funding organisations improving health and accessibility outcomes.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Astorg is a pan-European private equity firm with over €24 billion of assets under management and an 8th-generation buyout fund platform. Its core products are investment funds (Astorg VIII flagship €4.4bn, Astorg Mid-Cap €1.3bn, continuation funds including the Astorg Normec Continuation Fund and Astorg IQ-EQ Continuation Fund, plus historical funds I–VII), which acquire majority stakes in global B2B companies valued between €100m (Mid-Cap) and €500m+ (Flagship). Its portfolio companies operate as independent platforms across four core sectors — healthcare, technology, business services, and industrials — and are listed in detail above: notable healthcare platforms include CordenPharma (CDMO with €1bn+ peptide platform), Nexpring Health (ART MedTech), Echosens (FibroScan liver diagnostics), OPEN Health (medical communications), Avania, Cytel, Nemera, hg medical, Solabia (biotech ingredients), Demetra (orthopaedic biomaterials), and the pending acquisition of Thermo Fisher's microbiology business; technology and software platforms include IQ-EQ (investor services with ISO 27001 and €750bn AUA), Sofico (automotive leasing software), Acturis (insurance SaaS), Fenergo (KYC/CLM), Xceptor (data automation), Opus 2 (legal disputes software), Corsearch (brand protection), EcoVadis (sustainability ratings), Redslim (CPG/CHC data management), and Third Bridge (primary research); business services and industrials platforms include Normec (TICC services), Solina (food ingredients), Steliau (electronic solutions distribution, pending Acal BFI acquisition), Corialis (aluminium systems), IPCOM (insulation distribution), Lebronze Alloys (specialty copper alloys), Audiotonix (professional audio mixing consoles), IGM Resins (UV-curable materials), and ARMOR-IIMAK (thermal transfer ribbons); along with recently acquired or pending acquisitions IPL (infection prevention devices) and Barkene (multi-specialist B2B technical services). Beyond funds and portfolio companies, Astorg also operates Astorg Philanthropy Investments (API), a venture philanthropy arm launched in 2022 to fund organisations improving health and accessibility outcomes for people with disabilities and chronic conditions.

Product and service7 records
1Astorg VIII
CategoryFlagship buyout fund
Description

Astorg's 8th generation flagship buyout fund, sized at €4.4 billion, raised in 2023 and currently in its investment phase. Targets majority positions in global B2B companies valued at €500m and above, headquartered in Europe or the US, with expertise in healthcare, software, B2B professional services and technology-based industrials.

2Astorg Mid-Cap
CategoryMid-market buyout fund
Description

Astorg's mid-market buyout fund sized at €1.3 billion, raised in 2022. Targets majority positions in global B2B companies valued between €100 million and €400 million across healthcare, technology, business services and industrials.

3Astorg Normec Continuation Fund
CategoryContinuation fund
Description

A €1.4 billion continuation fund raised in 2024 in partnership with CVC Secondary Partners, Pantheon, Lexington Partners and Eurazeo to support portfolio company Normec, a leading European provider of testing, inspection, certification and compliance (TICC) services. Marked as Fully Invested.

4Astorg IQ-EQ Continuation Fund
CategoryContinuation fund
Description

A continuation fund launched in 2022 supporting Astorg's portfolio company IQ-EQ, a leading global investor services group providing compliance, administration, asset and advisory services to investment funds, global companies, family offices and private clients. IQ-EQ employs 4,750+ people in 25 jurisdictions with assets under administration exceeding US$750 billion.

5Astorg VII
CategoryFlagship buyout fund (prior vintage)
Description

Astorg's 7th generation buyout fund sized at €4.2 billion, raised in 2019. Includes investments such as IQ-EQ, Fastmarkets, Corialis, Corsearch, Xceptor, Cytel, Solina, Audiotonix, Normec, LGC and Nemera. Limited partner base included pension funds (30%), insurance companies (19%) and asset managers (18%).

6Astorg VI
CategoryFlagship buyout fund (prior vintage)
Description

Astorg's 6th generation buyout fund sized at €2.1 billion, raised in 2016.

7Astorg Philanthropy Investments (API)
CategoryVenture philanthropy program
Description

Astorg's venture philanthropy arm launched in 2022 under the auspices of the King Baudouin Foundation. Provides catalytic support through grants, equity, loans, blended finance and indirect investments (€30k–€300k per organisation) to non-profits and early-stage companies improving health and accessibility outcomes for people living with disabilities and chronic conditions across Europe, US, Canada, and Israel.

Recent move12 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Paris-based PE firm (~€28bn AUM). PAI is a direct French and European mid-/large-cap buyout competitor, often competing head-to-head with Astorg for European platform deals.

TypeDirect peer
Description

London-based global PE firm (~€80bn AUM). Permira competes directly with Astorg in European large-cap buyouts, particularly in technology, healthcare and consumer services.

3Ardian
TypeDirect peer
Description

Paris-headquartered pan-European PE firm with ~$160bn AUM. Ardian is a direct competitor in mid- and large-cap European buyouts — it sold Solina to Astorg in 2021 — and competes head-to-head in French and European deal flow.

TypeDirect peer
Description

Paris-headquartered listed PE firm (~€35bn AUM). Eurazeo co-invested in the Astorg Normec Continuation Fund in 2024 and competes directly in French mid- and large-cap buyouts, making it a natural European PE peer.

TypeDirect peer
Description

Stockholm-based PE firm focused on healthcare, technology and financial services. Nordic Capital co-invested with Astorg in Cytel and Clario and is a direct competitor in European healthcare buyouts.

TypeBroad incumbent
Description

Stockholm-headquartered global PE/VC firm (~€269bn AUM). EQT operates across healthcare, technology and industrials — overlapping with Astorg's vertical focus but at significantly greater scale and broader strategy scope.

TypeDirect peer
Description

London-headquartered pan-European mid- and large-cap PE firm (~€40bn AUM). Bridgepoint co-invested with Astorg on Fenergo, making it a direct comparable for European mid-cap and large-cap buyout activity.

TypeDirect peer
Description

London-headquartered PE firm (~€40bn AUM). BC Partners is a direct competitor in European large-cap buyouts, particularly across consumer, healthcare and business services verticals.

TypeDirect peer
Description

Pan-European private equity firm of broadly comparable AUM scale (~€186bn AUM). CVC is a direct competitor for large-cap European buyouts and co-invests alongside Astorg in deals such as LGC and Normec, making it the most direct peer in the European mega-cap LBO market.

TypeDirect peer
Description

London-based pan-European PE firm. Cinven co-invested with Astorg in LGC and was part of the Clario exit consortium. Operates in similar European large-cap healthcare and business services buyouts.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles20 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A54 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment21 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Astorg

Private Equity Fund Managementastorg.com

Astorg is a pan-European private equity firm managing €24bn AUM across flagship, mid-cap and continuation buyout funds, investing in global B2B companies across healthcare, technology, business services and industrials. Founded in 1998 and headquartered in Paris, it serves institutional limited partners and has delivered a 27% gross annualized return since inception.

What Astorg does

Astorg is a pan-European private equity firm founded in 1998 by Thierry Timsit and headquartered in Paris, France, with additional offices in London, Frankfurt, Milan, Luxembourg and New York. The firm operates through three wholly-owned regulated entities — Astorg Partners (AMF-regulated in France since 1998), Astorg Asset Management (CSSF-regulated in Luxembourg since 2015), and Astorg Advisory LLC (US sub-advisory) — and manages a fund family spanning eight generations of flagship buyout funds, a mid-cap vehicle, and continuation funds, reaching €24bn of assets under management with a 27% gross annualized return since inception across 27 years of investing.

Astorg's core products are its investment funds, which acquire majority stakes in global B2B companies: the Astorg VIII flagship buyout fund (€4.4bn, 2023 vintage) targets companies valued at €500m+; Astorg Mid-Cap (€1.3bn, 2022) targets €100-€400m companies; and continuation funds (Astorg Normec €1.4bn, Astorg IQ-EQ) provide liquidity and growth capital to existing portfolio companies. The firm invests across four verticals — healthcare, technology, business services, and technology-based industrials — with notable platforms including CordenPharma (pharmaceutical CDMO), IQ-EQ (investor services), Solina (food ingredients), Audiotonix (professional audio), Acturis (insurance SaaS), Fenergo (KYC/CLM), EcoVadis (sustainability ratings), Normec (TICC), and pending acquisitions of Thermo Fisher's microbiology business, Barkene, and Steliau/Acal BFI.

Astorg generates revenue primarily through recurring management fees on assets under management across its flagship, mid-cap and continuation fund vehicles, supplemented by performance-based carried interest participation in fund profits (supporting the reported 27% gross annualized return) and transaction-related fees on co-investments with limited partners. The firm serves institutional LPs (pension funds, insurance companies, asset managers, sovereign wealth funds, endowments and family offices) and operates an ancillary venture philanthropy arm, Astorg Philanthropy Investments, which deploys €30k-€300k cheques into health and accessibility-focused organizations under the King Baudouin Foundation. In April 2026, Astorg executed an 'internal LBO' granting new partners nearly 50% of firm equity while Thierry Timsit remained Executive Chairman, marking a generational ownership transition.

Astorg firmographics

Firmographics
Name
Astorg
Legal name
ASTORG PARTNERS
Website
https://astorg.com
Company type
Private
Founded year
1998
Operating status
Operating
Headcount range
101–250 employees
Short description
Astorg is a pan-European private equity firm managing €24bn AUM across flagship, mid-cap and continuation buyout funds, investing in global B2B companies across healthcare, technology, business services and industrials. Founded in 1998 and headquartered in Paris, it serves institutional limited partners and has delivered a 27% gross annualized return since inception.
Ownership category
akta.pro rank

Astorg industry classification

Industry
Product category
Private Equity Fund Management
NAICS
Portfolio Management and Investment Advice (52394)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANALAI
Operator-Led / CEO-in-Residence ETA
Financial & Insurance/Private Equity & Venture Capital/Search Funds / Entrepreneurship Through Acquisition (ETA)
SECONDARYFSANALAH
Family Office–Backed ETA
Financial & Insurance/Private Equity & Venture Capital/Search Funds / Entrepreneurship Through Acquisition (ETA)

Keywords

  • Private equity investing
  • Buyout fund management
  • Mid-market acquisitions
  • Healthcare technology investing
  • Business services investing

Where Astorg is headquartered

Location

Headquarters

HQ city
Paris
HQ country
France
HQ region
Europe

Markets served

Astorg business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Management Fees: Recurring fees charged on assets under management across flagship, mid-cap and continuation funds (e.g., Astorg VIII €4.4bn, Astorg VII €4.2bn, Astorg Mid-Cap €1.3bn, Astorg Normec Continuation Fund €1.4bn). Management fees fund the Astorg Philanthropy Investments arm.
  2. Carried Interest: Performance-based participation in fund profits, supporting the firm's reported 27% gross annualised return since 1998 across multiple fund vintages.
  3. Co-Investment Fees and Revenues: Meaningful co-investment opportunities offered to investor partners as an integral part of the value creation proposition; Astorg has invested over €19bn in businesses including co-invests.
  4. Alternative Investment Fund Management Fees: Fees from managing FPCI/AIF funds subject to French law and Luxembourg-law AIFs via Astorg Asset Management (CSSF-regulated).

Pricing tiers

ModelBillingPrice
Other—PRIIP Key Information Documents published for Astorg VII, Astorg MidCap and Astorg VIII
Other—Astorg Philanthropy Investments (API) cheque size range

Go-to-market motion1 record

Astorg product offering

Product offering

Core offering

Astorg is a private equity firm that raises and manages buyout fund vehicles — flagship (Astorg VIII €4.4bn), mid-cap (Astorg Mid-Cap €1.3bn), and continuation funds (Astorg Normec €1.4bn, Astorg IQ-EQ) — and deploys that capital to acquire majority equity stakes in global B2B companies valued between €100m (mid-cap) and €500m+ (flagship), headquartered in Europe or the US, across four sectors: healthcare, technology, business services, and technology-based industrials. The firm also operates Astorg Philanthropy Investments (API), a venture philanthropy arm funding organisations improving health and accessibility outcomes.

Product overview

Astorg is a pan-European private equity firm with over €24 billion of assets under management and an 8th-generation buyout fund platform. Its core products are investment funds (Astorg VIII flagship €4.4bn, Astorg Mid-Cap €1.3bn, continuation funds including the Astorg Normec Continuation Fund and Astorg IQ-EQ Continuation Fund, plus historical funds I–VII), which acquire majority stakes in global B2B companies valued between €100m (Mid-Cap) and €500m+ (Flagship). Its portfolio companies operate as independent platforms across four core sectors — healthcare, technology, business services, and industrials — and are listed in detail above: notable healthcare platforms include CordenPharma (CDMO with €1bn+ peptide platform), Nexpring Health (ART MedTech), Echosens (FibroScan liver diagnostics), OPEN Health (medical communications), Avania, Cytel, Nemera, hg medical, Solabia (biotech ingredients), Demetra (orthopaedic biomaterials), and the pending acquisition of Thermo Fisher's microbiology business; technology and software platforms include IQ-EQ (investor services with ISO 27001 and €750bn AUA), Sofico (automotive leasing software), Acturis (insurance SaaS), Fenergo (KYC/CLM), Xceptor (data automation), Opus 2 (legal disputes software), Corsearch (brand protection), EcoVadis (sustainability ratings), Redslim (CPG/CHC data management), and Third Bridge (primary research); business services and industrials platforms include Normec (TICC services), Solina (food ingredients), Steliau (electronic solutions distribution, pending Acal BFI acquisition), Corialis (aluminium systems), IPCOM (insulation distribution), Lebronze Alloys (specialty copper alloys), Audiotonix (professional audio mixing consoles), IGM Resins (UV-curable materials), and ARMOR-IIMAK (thermal transfer ribbons); along with recently acquired or pending acquisitions IPL (infection prevention devices) and Barkene (multi-specialist B2B technical services). Beyond funds and portfolio companies, Astorg also operates Astorg Philanthropy Investments (API), a venture philanthropy arm launched in 2022 to fund organisations improving health and accessibility outcomes for people with disabilities and chronic conditions.

Differentiator

Problem solved

Functional benefit

Brands

  • Astorg Mid-Cap: Astorg's separately marketed mid-market fund family for investments valued between €100m and €400m; raised as a €1.3bn fund vehicle in 2022.
  • Astorg Flagship
  • Astorg Philanthropy Investments (API)

Products and services

  • Astorg VIII Astorg's 8th generation flagship buyout fund, sized at €4.4 billion, raised in 2023 and currently in its investment phase. Targets majority positions in global B2B companies valued at €500m and above, headquartered in Europe or the US, with expertise in healthcare, software, B2B professional services and technology-based industrials.
  • Astorg Mid-Cap Astorg's mid-market buyout fund sized at €1.3 billion, raised in 2022. Targets majority positions in global B2B companies valued between €100 million and €400 million across healthcare, technology, business services and industrials.
  • Astorg Normec Continuation Fund A €1.4 billion continuation fund raised in 2024 in partnership with CVC Secondary Partners, Pantheon, Lexington Partners and Eurazeo to support portfolio company Normec, a leading European provider of testing, inspection, certification and compliance (TICC) services. Marked as Fully Invested.
  • Astorg IQ-EQ Continuation Fund A continuation fund launched in 2022 supporting Astorg's portfolio company IQ-EQ, a leading global investor services group providing compliance, administration, asset and advisory services to investment funds, global companies, family offices and private clients. IQ-EQ employs 4,750+ people in 25 jurisdictions with assets under administration exceeding US$750 billion.
  • Astorg VII Astorg's 7th generation buyout fund sized at €4.2 billion, raised in 2019. Includes investments such as IQ-EQ, Fastmarkets, Corialis, Corsearch, Xceptor, Cytel, Solina, Audiotonix, Normec, LGC and Nemera. Limited partner base included pension funds (30%), insurance companies (19%) and asset managers (18%).
  • Astorg VI Astorg's 6th generation buyout fund sized at €2.1 billion, raised in 2016.
  • Astorg Philanthropy Investments (API) Astorg's venture philanthropy arm launched in 2022 under the auspices of the King Baudouin Foundation. Provides catalytic support through grants, equity, loans, blended finance and indirect investments (€30k–€300k per organisation) to non-profits and early-stage companies improving health and accessibility outcomes for people living with disabilities and chronic conditions across Europe, US, Canada, and Israel.

Companies that use Astorg

Customer profile

Ideal customer profiles3 records

Astorg technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Astorg partnerships and signals

Strategic signal

Recent moves12 records

Expansion highlights5 records

Astorg competitors and assessment

Company assessment

Direct peers

  • PAI Partners: Paris-based PE firm (~€28bn AUM). PAI is a direct French and European mid-/large-cap buyout competitor, often competing head-to-head with Astorg for European platform deals.
  • Permira: London-based global PE firm (~€80bn AUM). Permira competes directly with Astorg in European large-cap buyouts, particularly in technology, healthcare and consumer services.
  • Ardian: Paris-headquartered pan-European PE firm with ~$160bn AUM. Ardian is a direct competitor in mid- and large-cap European buyouts — it sold Solina to Astorg in 2021 — and competes head-to-head in French and European deal flow.
  • Eurazeo: Paris-headquartered listed PE firm (~€35bn AUM). Eurazeo co-invested in the Astorg Normec Continuation Fund in 2024 and competes directly in French mid- and large-cap buyouts, making it a natural European PE peer.
  • Nordic Capital: Stockholm-based PE firm focused on healthcare, technology and financial services. Nordic Capital co-invested with Astorg in Cytel and Clario and is a direct competitor in European healthcare buyouts.
  • Bridgepoint: London-headquartered pan-European mid- and large-cap PE firm (~€40bn AUM). Bridgepoint co-invested with Astorg on Fenergo, making it a direct comparable for European mid-cap and large-cap buyout activity.
  • BC Partners: London-headquartered PE firm (~€40bn AUM). BC Partners is a direct competitor in European large-cap buyouts, particularly across consumer, healthcare and business services verticals.
  • CVC Capital Partners: Pan-European private equity firm of broadly comparable AUM scale (~€186bn AUM). CVC is a direct competitor for large-cap European buyouts and co-invests alongside Astorg in deals such as LGC and Normec, making it the most direct peer in the European mega-cap LBO market.
  • Cinven: London-based pan-European PE firm. Cinven co-invested with Astorg in LGC and was part of the Clario exit consortium. Operates in similar European large-cap healthcare and business services buyouts.

Broad incumbents

  • EQT Partners: Stockholm-headquartered global PE/VC firm (~€269bn AUM). EQT operates across healthcare, technology and industrials — overlapping with Astorg's vertical focus but at significantly greater scale and broader strategy scope.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Astorg social profiles

Digital presence

Astorg compliance and trust

Trust signal

Compliance6 records

Astorg financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Astorg leadership team

Management profile

Number of profiles

Profiles20 records

Astorg subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Astorg funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Astorg M&A and investment

M&A and investment

M&A54 records

Investments21 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Astorg

What does Astorg do?

Astorg is a private equity firm that raises and manages buyout fund vehicles — flagship (Astorg VIII €4.4bn), mid-cap (Astorg Mid-Cap €1.3bn), and continuation funds (Astorg Normec €1.4bn, Astorg IQ-EQ) — and deploys that capital to acquire majority equity stakes in global B2B companies valued between €100m (mid-cap) and €500m+ (flagship), headquartered in Europe or the US, across four sectors: healthcare, technology, business services, and technology-based industrials. The firm also operates Astorg Philanthropy Investments (API), a venture philanthropy arm funding organisations improving health and accessibility outcomes.

Is Astorg a public or private company?

Astorg is a private company. It is classified as management employee owned and is currently operating.

When was Astorg founded?

Astorg was founded in 1998. It employs 101 to 250 people.

Where is Astorg based?

Astorg is headquartered in Paris, France, in the Europe region.

How does Astorg make money?

Four revenue lines are on record. Management Fees are the primary driver. The others are carried Interest, co-Investment Fees and Revenues and alternative Investment Fund Management Fees.

Who are Astorg's main competitors?

Direct peers on record are PAI Partners, Permira, Ardian, Eurazeo, Nordic Capital, Bridgepoint, BC Partners, CVC Capital Partners and Cinven. EQT Partners is listed as a broad incumbent.

Does Astorg have an API?

No public API is recorded for Astorg.

What industry is Astorg in?

Astorg's product category is Private Equity Fund Management. Its primary akta.pro industry code is FSANALAI, Operator-Led / CEO-in-Residence ETA, with a secondary code of FSANALAH, Family Office–Backed ETA. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Private Equity InternationalAstorg’s Olivier Lieven: Mid-cap PE has ‘role to play’ in medtech carve-outs; KPS to buy packaging division from MM Group for €2.4bnKPS Capital Partners signed a definitive agreement to acquire MM Packaging from MM Group for €2.4bn. Astorg agreed to sell iGM Resins after navigating the company through a challenging period for the European chemicals sector.EIN PresswireAstorg plans for Oxoid Remel to acquire Solabia’s microbiology diagnostics division | PE HubAstorg plans for Oxoid Remel to acquire Solabia's microbiology diagnostics division, which includes Biokar Diagnostics. The division focuses on microbiological culture media, particularly for food and beverage testing.PrivateequitywireBridgepoint, Astorg weigh £2bn-plus sale of Fenergo - Private Equity WireBridgepoint and Astorg are considering selling Irish financial software firm Fenergo for over £2bn, with preliminary buyer talks underway. A formal sale process could start in Q1 2027, potentially involving financial and strategic bidders. Fenergo reported 7.5% revenue growth to €149.4m for the year ended March 2025.ReutersBridgepoint, Astorg consider £2 billion-plus Fenergo sale, sources sayBridgepoint and Astorg are considering selling Fenergo, an Irish fintech, to a potential buyer, with one source saying it could be valued at more than £2 billion. The firms have held discussions with buyers and may appoint an investment bank later this year. A sales process could launch early in 2027.Channel NewsAsiaExclusive-Bridgepoint, Astorg consider £2 billion-plus Fenergo sale, sources sayBridgepoint and Astorg are considering selling Fenergo, an Irish fintech, for over £2 billion, with discussions ongoing and a sale process potentially launching in early 2027. Fenergo's revenue rose 7.5% to €149.4 million for the year ending March 2025, and operating profit increased 66% to €20.9 million.The future of tradingBridgepoint, Astorg consider £2 billion-plus Fenergo sale, sources sayBridgepoint and Astorg are considering selling Fenergo, an Irish fintech, for more than £2 billion ($2.7 billion), according to three sources. The firms have discussed with buyers and may launch a sales process early in 2027. Fenergo's revenue rose 7.5% to €149.4 million for the year ending March 2025.PR Newswire APACCordenPharma Appoints Dr. Jean-Luc Herbeaux as Chief Executive Officer to Lead Next Phase of GrowthCordenPharma appointed Dr. Jean-Luc Herbeaux as CEO effective 1 October 2026, succeeding Dr. Michael Quirmbach, who will remain as Board Member and Senior Advisor. Herbeaux joins from Hovione, where he served as CEO for over four years. The transition follows 12 years of growth under Quirmbach, including revenue growth from €245 million to over €1 billion.BioSpace/C O R R E C T I O N -- CordenPharma/CordenPharma announced a €80 million multi-year investment to boost its sterile injectable capacity at the Caponago site to 500 million units per year. The expansion includes a new 11,000 m² building and two new isolator lines, with completion targeted for mid-2027 and 2028.PR Newswire APAC/C O R R E C T I O N -- CordenPharma/CordenPharma announced a €80 million multi-year investment to expand its sterile injectable CDMO capacity at its Caponago, Italy site. The expansion adds an 11,000 m² facility and two new isolator lines, projecting total capacity up to 500 million injectable units per year. Completion is targeted for mid-2027 and 2028.PR Newswire/C O R R E C T I O N -- CordenPharma/CordenPharma announced a €80 million multi-year investment to expand its sterile injectable CDMO capacity at its Caponago, Italy site. The expansion adds an 11,000 m² facility and two new isolator lines, projecting total capacity up to 500 million units per year. Completion is targeted for mid-2027 and 2028.